United Kingdom
GitLife Biotech, founded in 2023 and headquartered in the United Kingdom, is a pioneering character in the biotechnology landscape. The company focuses on optimizing the management of bio-assets and intellectual property (IP) through its innovative platform called CellRepo. Touted as "GitHub for Biology," this platform addresses the longstanding issue of IP disputes and losses in synthetic biology by enhancing traceability and security from initial research to commercialization.
Biotech advancements often face hurdles like outdated tracking methods and an absence of version control, which result in exposure of IP and related revenue losses. GitLife Biotech has engaged with numerous industry professionals, affirming the urgent need for their solution. Their bio-digital innovation allows for barcoded, traceable cells and a tamper-proof chain of custody, ensuring efficient ownership proof and integration with existing lab processes.
The company's pre-seed funding, completed on 27 February 2023, was led by Mandashi and Cambridge Future Tech, marking its potential as a disruptor in the biotechnology industry.
